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1 Science-based discovery
Monoclonal antibodies (mAbs) have become a crit-
ical component of clinical treatment regimens for a
variety of indications. Their application ranges
from cancer, inflammation, cardiovascular dis-
eases, and transplant rejection to infectious dis-
ease. Drugs like trastuzumab, rituximab and inflix-
imab have demonstrated that mAbs can be used as
highly specific therapeutics, able to elicit signifi-
cant and prolonged clinical responses.Since the in-
troduction of the first US Food and Drug Adminis-
tration (FDA) approved therapeutic mAb (Ortho-
clone OKT3, muromonab-CD3) into the clinic, 21
more antibodies have been approved for use in hu-
mans, and many companies have antibody prod-
ucts well advanced in clinical development.
Even though mAbs have brought major ad-
vances to the clinical practice, it is clear that there
remains room for improvement. Indeed, subsets of
patients are not responding to initial antibody
treatment, or become resistant to (re)treatment.
Research on the identification of biomarkers that
allow the prediction of responding patients has
shown that besides target expression and state,
biomarkers such as antibody-binding Fc receptors
and immune-modulatory molecules also impact
clinical outcome.
Moreover, antibodies can exert their action in a
variety of ways, ranging from target modulation,
neutralization of soluble targets (such as cy-
tokines),disruption of ligand-receptor interactions
and influencing cell signaling, to engagement of
immune effector functions such as antibody-de-
pendent cellular cytotoxicity (ADCC) and comple-
ment-dependent cytotoxicity (CDC). The mecha-
nisms of action of a therapeutic antibody strongly
influence its application and clinical potential. Es-
pecially in oncology, it is observed that successful
mAbs can exert multiple mechanisms of action. In
cancer therapy, a therapeutic agent needs to (at
least) control malignant cell growth,and preferably
be able to kill and eradicate the target cells. mAbs
have, in this respect, a double benefit: not only do
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they have the ability to directly interfere with cell
growth, they can also specifically activate the im-
mune system to induce cell lysis or phagocytosis.
Applying this knowledge in the discovery of
new therapeutic mAbs makes it possible to im-
prove the panels of antibodies generated,and to se-
lect the best candidates for clinical development.
At Genmab, we use this science-based approach 
to generate fully human antibodies for a variety of
indications, with a strong focus on oncology. We 
describe here how this has resulted in the deve-
lopment of three mAbs that are now in Phase III 
clinical trials in various cancer indications: zano-
limumab (directed against CD4), ofatumumab 
(directed against CD20) and zalutumumab (direct-
ed against epidermal growth factor receptor,
EGFR).
2 Tackling immunogenicity
Like other therapeutic proteins, antibodies can be
immunogenic, and the generation of anti-antibody
responses may pose safety concerns. In addition,
anti-antibody responses can influence pharmaco-
kinetics,or reduce efficacy of the injected antibody
through neutralization.
The first therapeutic mAbs were of mouse ori-
gin (indicated by the suffix -omab in INN nomen-
clature;see Fig.1 for more explanation on antibody
nomenclature), and frequently caused infusion re-
actions that could be as severe as anaphylactic re-
sponses [1].To tackle this problem, molecular bio-
logical approaches were used to replace part of the
rodent antibody sequence for human sequences [2,
3], resulting in chimeric or humanized molecules
(suffixes –ximab and –zumab in INN nomenclature
Fig. 1). Even better, technologies now exist to gen-
erate fully human antibodies (suffix –umab). We
employ transgenic mice, in which the murine anti-
body genes have been inactivated and replaced by
human antibody genes (human Ig transgenic mice,
[4]). In these mice, normal somatic hypermutation,
affinity maturation and class switching occurs fol-
lowing repeated immunizations, resulting in high-
affinity antibodies.Immunization,fusion of B cells,
and hybridoma propagation use similar approach-
es as in classical monoclonal production, but now
with fully human antibodies as the end product.
The transgenic mouse platform employed includes
several mouse strains, each containing DNA en-
coding parts of the human variable region antibody
repertoire and varying human constant regions.
Typically, the mice contain at least a human kappa
light chain transgene and transgenes for human μ,
and γ1 heavy chains [4,5].Selection for the desired
IgG subclass can be included in the antibody selec-
tion process, or alternatively the subclass can be
adapted using standard molecular biological tech-
niques in the process of developing a stable recom-
binant cell line required for large scale production.
In contrast to human antibodies derived from
other technologies such as phage display (when
based on naïve libraries), antibodies from trans-
genic mice do not require any further engineering.
Indeed, the available literature on the drug discov-
ery of transgenic mouse-derived antibodies indi-
cates that they typically move directly from lead se-
lection into clinical development. In contrast, lead
optimization of phage display-derived antibodies
to improve affinity is often described as an integral
part of their development (reviewed in [6]).As clin-
ical experience with fully human antibodies de-
rived from both these technologies is limited, it is
Figure 1. Classification of therapeutic
antibodies in cancer. Progress in genet-
ic engineering has facilitated the devel-
opment of fully human therapeutic
mAbs. Original mAb technologies yield-
ed murine (and in some cases rat) mol-
ecules. Chimeric antibodies are geneti-
cally engineered mAb with murine vari-
able regions (VL and VH) and constant
regions derived from a human source.
Humanized therapeutic mAb closely
match the human germline sequence
except for CDR, which are of murine
(and occasionally rat) origin. The inset
table explains the nomenclature of 
therapeutic antibodies in cancer indica-
tions, according to the system of Inter-
national Nonproprietary Names (INN).© 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 1159
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currently unresolved whether the introduction of
novel sequences during lead optimization impacts
immunogenicity.
There are a number of factors that may influ-
ence the immunogenicity of a therapeutic protein.
Not only structural properties of the protein itself
(as discussed below), but also ‘external’ factors
such as drug impurities, formulation, route of ap-
plication, dose and length of treatment may influ-
ence immune responses to therapeutics [7]. In ad-
dition, patient characteristics, including genetic
background, disease state and concomitant treat-
ments, determine whether antibody responses are
elicited.
The presence of so-called T helper cell epitopes
in the therapeutic protein itself can contribute to its
immunogenicity. In the generation of an antibody
response, (foreign) proteins are taken up by anti-
gen-presenting cells (APC), and processed intra-
cellularly into small peptides that are exposed on
the APC surface in the context of major histocom-
patibility complex class II molecules (MHC II, in
humans also known as human leukocyte antigens,
HLA).These peptides, or epitopes, are then recog-
nized by T helper cells, which are activated to pro-
liferate and differentiate. T helper cells in turn
stimulate specific B cells to produce antibodies di-
rected against the antibody drug to produce anti-
antibodies1.The MHC/HLA II locus is highly vari-
able, and numerous MHC/HLA allotypes exist,
which all have their own peptide specificities.
Classically, identification of T helper cell epi-
topes is performed by in vitro tests using human
blood cells. Nowadays, more sophisticated in silico
approaches exist,which are powerful tools to allow
mapping of epitopes from virtually all HLA allo-
types. In particular, structure-based methods have
been found to reliably predict T helper epitopes [8].
We have used one such method,Epibase® [8],to in-
vestigate whether the expected low immunogenic-
ity of fully human antibodies can be confirmed
(Table 1). This method not only predicts T helper
epitopes, but also indicates peptide affinities for
HLA allotypes. A striking result from these analy-
ses was that the numbers of predicted strong bind-
ing T helper epitopes of zanolimumab, ofatumum-
ab as well as zalutumumab were very low indeed.
Direct comparison of, for instance, ofatumumab to
rituximab, a chimeric CD20 antibody that has been
on the market since 1997, revealed ofatumumab to
contain at least four times less T helper epitopes
(Table 1) [8].We compared our antibodies not only
to chimeric or humanized products, where large
differences can be expected,but also head-to-head
for zalutumumab and panitumumab.The latter is a
fully human antibody against EGFR, derived from
another transgenic mouse platform developed by
Abgenix (now Amgen) [9]. Remarkably, two times
more strong-binding epitopes for HLA DRB1 were
found in panitumumab compared to zalutumumab
(Table 1). As expression levels of HLA DR1 are
(much) higher than those of DQ and DP , binding
epitopes for DR1 molecules are considered to rep-
resent the most important differentiators in im-
munogenicity of proteins. The transgenic mouse
platform (Xenomouse®) used to generate panitu-
mumab and the UltiMAb® platform [10] employed
to generate zanolimumab,zalutumumab and ofatu-
mumab contain differences in VH,-, D- and J-gene
repertoire in a distinct MHC background. In addi-
tion, the specific strain used to generate panitu-
mumab did not contain a Cγ1 gene (and only con-
tained the human Cγ2 gene instead). This could
have contributed to the differences found.
The first data on immunogenicity in a clinical
setting confirm that our human antibodies do not
elicit strong immune responses.In a Phase II study
in refractory cutaneous T cell lymphoma (CTCL),
only 1 out of 47 patients receiving zanolimumab
developed a titer of human anti-human antibodies
that was marginally above background [11].There
was no indication that this human anti-human
antibody response was neutralizing the effect of
zanolimumab. In contrast, initial studies with
chimeric CD4 antibodies in this indication [12]
showed that already after a short-term treatment 2
out of 7 patients developed human anti-chimeric
antibodies. The first results for ofatumumab
showed that this molecule did not elicit human
anti-human antibodies [13].
Table 1. Number of strong binding T helper epitopes (Kd <100 nM, [8])
identified by Epibase present in CD4-binding antibodies Zanolimumab
and chimeric Leu3a-, CD20-binding antibodies ofatumumab and ritux-
imab, and EGFR-binding antibodies zalutumumab, cetuximab and panitu-
mumab. Results are split up per human leukocyte antigen class II type
Target Antibody DRB1 DRB3/4 DQ DP
CD4 Zanolimumab 7131
Chimeric Leu3a 10 2 2 0
CD20 Ofatumumab 4022
Rituximab 16 2 4 1
EGFR Zalutumumab 3231
Cetuximab 16 2 3 3
Panitumumab 7020
1 The anti-antibody responses in humans are abbreviated according to the
type of molecule they are directed against: HAMA for human anti-murine
antibodies, HACA for human anti-chimeric antibodies and HAHA for hu-
man anti-humanized or human anti-human antibodies.Biotechnology
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Another, very powerful, in silico approach to
identify potential immunogenicity is the ‘collier de
perles’ analysis and direct comparison of the nu-
cleotide and amino acid sequences of the V do-
mains of antibodies as provided by the IMTG data-
base [14]. This approach provides a standard de-
limitation of the framework regions and comple-
mentarity determining regions (CDRs), and allows
comparisons to the closest germline sequences of
these regions.As an illustration of the usefulness of
this approach,Magdelaine-Beuzelin et al.[14] ana-
lyzed a number of chimeric and humanized anti-
bodies (cetuximab, rituximab, alemtuzumab, beva-
cizumab and trastuzumab).They described an ex-
pected low percentage of identity of chimeric anti-
bodies to the most similar human germline
sequence (55–80% identity). Remarkably, human-
ized antibodies fell in this same range,with 72–80%
identity to human germline. Antibody responses
have been reported to all chimeric and humanized
antibodies currently in the clinic (for a compre-
hensive overview, see [8]). Although the incidence
of such antibody responses has certainly not been
documented in all patient groups [for instance,
anti-rituximab responses are readily found in au-
toimmune disease patients, but not in non-
Hodgkin’s lymphoma (NHL) patients], identifica-
tion of apparent deviations from germline se-
quences could aid in the design and perfection of
therapeutic antibodies. We have screened zanoli-
mumab, ofatumumab and zalutumumab against
the IMTG human reference directory (Neijssen et
al., manuscript in preparation), and observed that
the VH and Vκ sequences of these three antibodies
are remarkably close to germline.When comparing
the V region sequences with the closest human se-
quences found, the percentage of identity ranged
from 97% to 100%.
Overall, independent methods to examine im-
munogenicity of zanolimumab, ofatumumab and
zalutumumab substantiate that the human Ig
transgenic mouse platform generates fully human
antibodies with favorably low immunogenicity pro-
files,which are expected to pose low safety risks in
the clinic.
3 Zanolimumab: Changing CD4+ T cell 
activation and survival
The CD4 molecule is a single-chain transmem-
brane glycoprotein of 55 kDa that consists of four
extracellular Ig-like domains and a short cytoplas-
mic tail. CD4 is mainly expressed on T helper cells
and monocytes and serves as a co-receptor for the
T cell receptor (TCR)/CD3 complex. The function
of CD4 is to enhance antigen-mediated activation
of T cells.This is achieved by stabilizing the adhe-
sion between T cells and APCs (association of CD4
and MHC II/peptide complex) and enhancing sig-
nal transduction of the TCR/CD3 complex [15, 16].
With CD4 playing a key role in immunity, thera-
peutic research of CD4 mAbs was initially focused
on inflammatory and (auto)immune diseases
[17–20]. Our fully human CD4 mAb zanolimumab
was assessed in Phase I/II clinical trials in rheuma-
toid arthritis and psoriasis. The predominant out-
come of these studies was that zanolimumab was
not only found safe and well tolerated,but most im-
portantly, it induced a significant T cell depletion
following repeat dosing [21]. Development of the
antibody was discontinued in inflammatory indica-
tions as it did not show a benefit over approved
drugs for these indications. However, the ability to
particularly deplete memory type T cells [21, 22]
suggested the potential of zanolimumab to treat T
cell cancers (see below).
Zanolimumab (clone 6G5, [5]) was among the
first fully human mAbs generated from human Ig
Figure 2. Mechanisms of action of zanolimumab, ofatumumab and zalutumumab. See text for further description.© 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 1161
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Table 2. Key results of clinical studies of zanolimumab, ofatumumab and zalutumumab 
Antibody/indication Publication Trial description Dose(s) Key results
Zanolimumab
Cutaneous T-cell  Kim YH et al. [11] Two Phase II, multi- Seventeen weekly  Forty-seven patients were
lymphoma (CTCL) center, prospective, i.v. infusion of 280,   included in the trial. In the high-
open-label, uncon- 560, or 980 mg  dose groups (560 and 980 mg),
trolled trials to evaluate  zanolimumab. an objective response rate of 
efficacy and safety in  56% was obtained in mycosis 
patients with treatment fungoides patients with a 
refractory CD4+ CTCL. median response of 81 weeks. 
Adverse effects (AEs) reported
most frequently included low-
grade infections and eczema-
tous dermatitis.
Non-cutaneous D’Amore  F et al. [70]  A open-label, exploratory  Twelve weekly i.v.  Twenty-one patients were in-
T cell lymphoma (abstract) trial to explore the effi- infusions of 980 mg  cluded in the trial. Objective 
cacy in patients with  zanolinumab. tumor response was obtained 
biopsy proven CD4+ peri- in 5 out of 21 patients (24%). 
pheral T cell lymphoma  AEs reported most frequently 
of non-cutaneous type  were rash not otherwise speci-
who were treatment- fied and pyrexia. No infections 
refractory or had relapsed. considered related to treatment
were reported.
Ofatumumab
Chronic lymphocytic  Coiffier et al. [13] A Phase I/II multicenter,  Four weekly i.v.  Thirty-three patients were in
leukemia (CLL) open-label, dose-esca- infusions of 1× 100 mg/ cluded in the trial, 3 in cohort A
lating trial in patients with  3× 300 mg (cohort A),  and B, and 27 in cohort C. The
relapsed or refractory CLL. 1× 300 mg/3× 1000 mg  maximum tolerated dose 
(cohort B), or 1× 500 mg/ (MTD) was not reached. The 
3× 1000 mg (cohort C). majority of related AEs occurred
at first infusion. Seventeen
(51%) patients experienced in-
fections, 88% of them of grade
1–2. One event of interstitial
pneumonia was fatal. The re-
sponse rate of cohort C was
50%.
Follicular Hagenbeek  A et al.  A Phase I/II open-label,  Four weekly i.v.  Forty patients were included in 
lymphoma (FL) [71] multicenter trial  infusions of 300, 500,  the trial. MTD was not reached.
evaluating safety, efficacy,  700, or 1000 mg in a  The majority of related AEs 
and pharmacokinetics  dose-escalating manner. occurred at first infusion and 
(PK) in patients with  was of grade 1–2. Eight related 
relapsed or refractory  events were of grade 3. The 
FL grade 1–2. best objective clinical response
across dose groups was 43%.
Median time to progression for
all patients/responders was
8.8/32.6 months and median
duration of response was
29.9 months at a median/
maximum follow-up of 9.2/
38.6 months. The median half-
life across dose groups was
410 h after the fourth dose.Biotechnology
Journal
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transgenic mice.Biochemical analyses of the panel
of antibodies from which zanolimumab was select-
ed showed the strength of the transgenic mouse
platform,being able to generate highly specific an-
tibodies with binding capacities (avidity) similar to
those of ‘classical’ murine mAbs.
Preclinical studies in non-human primates gave
the first indications for the CD4+ cell-depleting ca-
pacity of zanolimumab [23]. Bolus injection of
zanolimumab in cynomolgous monkeys signifi-
cantly depleted CD4+ cells from the blood, with re-
covery taking up to 160 days. A detailed study was
initiated to elucidate the mechanism(s) responsible
for the reduction of circulating CD4 cell numbers
by zanolimumab [22] (Fig.2).Zanolimumab strong-
ly inhibited T cell activation through two distinct,
complementary pathways. One of the earliest
events in the TCR signaling cascade, the phospho-
rylation of the TCR˙ chain, was inhibited by zanoli-
mumab. Interestingly, zanolimumab binding acti-
vates signaling through the CD4-associated tyro-
sine kinase p56LCK.Herein,the antibody uncouples
p56LCK from the TCR, which allows the kinase to
transmit direct inhibitory signals through inhibito-
ry adaptor molecules Dok-1 and SHIP-1.
In addition,Fc-dependent effector mechanisms
were studied. Although zanolimumab is of human
IgG1 isotype,and is intrinsically capable of activat-
ing complement (as determined in plate-bound as-
says),the antibody did not bind or activate comple-
ment when bound to CD4 on primary T cells. In
contrast, already at relatively low concentrations
zanolimumab induced potent NK cell-mediated
ADCC of primary CD4+T cells.Here,CD45RO+ pri-
mary T cells proved more sensitive to zanolimum-
ab-induced ADCC than naïve CD45RA+T cells.This
correlated well with the in vivo findings in psoria-
sis patients, where subcutaneous infusions (once
weekly for 4 weeks) resulted in a dose-dependent
decrease in the total lymphocyte counts, mainly
due to a reduction in CD4+ T cells in the memory
cell subset (CD3+, CD4+, CD45RO+) [21].
Zanolimumab also effectively induced CD4
down-modulation. This mechanism was found to
require CD4 clustering,and to be dependent on the
antibodies’ Fc region: whole antibody, but not
F(ab’)2 fragments, mediated a dose-dependent
CD4 down-regulation in the presence of mono-
cytes.
Hence, zanolimumab exerts its action through
inhibition of CD4+ T cell signaling in concert with
the induction of Fc-dependent ADCC and CD4
down-modulation (Fig. 2). This mechanism of ac-
tion profile, challenging CD4+ cells from three dif-
ferent angles,was recognized as being ideal for use
in a setting where malignant CD4+ T cells pose a
threat to patient survival. Such conditions are
found in cutaneous T cell lymphoma (CTCL) as
Figure 3. Clinical improvement of mycosis fun-
goides. Left panel shows baseline, right panel
shows clinical response 4 weeks after start 
of zanolimumab treatment. Adapted from [11].
Table 2. Key results of clinical studies of zanolimumab, ofatumumab and zalutumumab 
Antibody/indication Publication Trial description Dose(s) Key results
Zalutumumab
Squamous cell  Bastholt L et al.  A Phase I/II open-label,  A single i.v. infusion  Twenty-eight patients were in-
carcinoma of the  [64] multicenter trial  of HuMax-EGFR at  cluded in the trial. MTD was not 
head and neck  evaluating safety,  doses of 0.15, 0.5, 1, 2, reached. The most frequently 
(SCCHN) tolerability, PK, and  4, or 8 mg/kg i.v.  reported AE was rash (duration: 
efficacy in patients  (dose-escalating) a few days to 2 months). All but 
with SCCHN followed by four  one event were of grade 1–2 and 
weekly i.v. infusions at  a dose-dependent relationship 
the same doses  was indicated. In the two high-
(repeat dose extension). est dose groups, 7 of 11 patients
obtained a partial response (PR)
or stable disease (SD) and 9 
patients obtained metabolic PR
or SD.© 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 1163
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well as non-cutaneous T cell lymphoma.CTCL cov-
ers a range of diseases, including mycosis fun-
goides (MF) and Sézary syndrome, characterized
by infiltration of malignant T cells that express CD4
into the skin. The disease is incurable except at a
very early stage and is life threatening in the ad-
vanced stages. Histologically, MF is characterized
by the presence of Pautrier microabsesses, in
which malignant T cells accumulate in close prox-
imity to APCs [24–26]. It is believed that this close
interaction results in chronic stimulation and
growth of malignant cells.
Phase II studies in early and late stage CTCL
showed that zanolimumab induced a marked clini-
cal effect, with early, high and durable responses
[11] (summarized in Table 2; Fig. 3). At the high
dose levels,ten MF patients had objective respons-
es lasting between 8 and 91 weeks,with median re-
sponse durations of 81 weeks (20.3 months). A
Phase III pivotal trial is currently ongoing
(Table3),of which the first interim results indicates
a 42% objective response rate in the two highest
dose groups [27].
Overall, our approach shows that CD4 targeting
can be extended well beyond (auto)immune indi-
cations. By combining effective engagement of
ADCC with direct effects on CD4 expression and
signaling, we generated a promising new antibody
drug for the treatment of for CD4+ cell malignan-
cies.We are currently not only developing this an-
tibody for treatment of CTCL, but are also explor-
ing its potential in peripheral T cell lymphomas
(Table 3).
Table 3. Clinical development in cancer indications of zanolimumab, ofatumumab and zalutumumaba)
Zanolimumab
Previous studies
Zanolimumab in early stage CTCL CTCL Phase II
Zanolimumab in late stage CTCL CTCL Phase II
Zanolimumab in refractory and relapsed non-CTCL Non-CTCL Phase II
Ongoing studies
Zanolimumab in combination with CHOP chemotherapy in non-CTCL Non-CTCL Phase II combination study
Zanolimumab in CTCL refractory to standard therapy CTCL Phase III pivotal study
Ofatumumabb)
Previous studies
Ofatumumab in relapsed or refractory follicular NHL Follicular NHL Phase I/II
Ofatumumab in relapsed CLL CLL Phase I/II
Ongoing studies
Ofatumumab in follicular NHL refractory to rituximab therapies Follicular NHL Phase III pivotal study
Ofatumumab in combination with CHOP Follicular NHL Phase II combination study
Ofatumumab in refractory CLL CLL Phase III pivotal study
Ofatumumab in combination with fludarabine and cyclophosphamide CLL Phase II combination study
Ofatumumab in relapsed DLBCL DLBCL Phase II study
Zalutumumab
Previous studies
Zalutumumab in patients with recurrent or metastatic SCCHN SCCHN Phase I/II
Ongoing studies
Zalutumumab in combination with chemotherapy and radiotherapy  SCCHN Phase I/II combination study
in head and neck cancer
Zalutumumab in patients with non-curable head and neck cancer SCCHN Phase III pivotal study
DAHANCA 19: The importance of the EGFR-inhibitor zalutumumab  SCCHN Phase III study
for the outcome after curative radiotherapy for SCCHN
Zalutumumab in combination with chemo-radiation in lung cancer NSCLC Phase I/II combination study
Zalutumumab in non-curable patients with SCCHN SCCHN Phase II study
Zalutumumab with or without irinotecan chemotherapy in 
cetuximab-refractory colorectal cancer CRC Phase I/II combination study
a) Status in May 2008. For the most current information on clinical development of Zanolimumab, ofatumumab and zalutumumab, see www.genmab.com and
www.clinicaltrials.gov. CTCL, cutaneous T cell lymphoma; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin’s lymphoma; DLBCL, diffuse large B cell lym-
phoma; SCCHN, squamous cell carcinoma of the head and neck; CRC, colorectal cancer; NSCLC, non-small cell lung cancer
b) For ofatumumab, only studies in cancer indications are listed here. Ofatumumab is also in clinical development in rheumatoid arthritis and multiple sclerosis. Biotechnology
Journal
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4 Ofatumumab: Efficient inducer of CDC
through a unique binding epitope
CD20 is arguably one of the best-validated targets
for antibody therapy [28,29].On normal cells,CD20
is first expressed at the pre-B cell stage,before IgM
is expressed on the cell surface (Fig. 4). The ex-
pression of CD20 continues throughout B cell mat-
uration until the plasmacytoid immunoblast phase,
yet CD20 is not expressed on lymphoid stem cells
or plasma cells. In B cell malignancies, like B cell
NHL, CD20 is highly expressed. Besides being an
apparent target in oncology, CD20 targeting is now
also applied in autoimmune diseases, such as
rheumatoid arthritis.
CD20 represents a non-glycosylated,297-amino
acid (33–37 kDa) phosphoprotein that is predicted
to span the plasma membrane four times [30].Both
the N and C termini of the protein are located with-
in the cytoplasm.A large loop of 44 amino acids and
a much smaller loop of 7 amino acids are accessi-
ble from the extracellular milieu.
The function of CD20 is not known. It has been
suggested to play a role in B cell activation,the reg-
ulation of B cell growth, and transmembrane calci-
um flux.The structure of CD20 implies that it either
forms an ion channel or is associated with an ion
channel [31]. Interestingly, upon cross-linking in-
duced by a number of CD20 antibodies, CD20
translocates to cholesterol- and sphingolipid-rich
microdomains, so-called ‘lipid rafts’ [32].A central
feature of these rafts is their ability to selectively
include or exclude membrane proteins.Transloca-
tion into lipid rafts is an extremely rapid process,
and is directly followed by phosphorylation of typ-
ical raft proteins like the protein tyrosine kinase
Lyn, which initiates signaling cascades. This indi-
cates that translocation of CD20 into lipid rafts is
necessary to trigger signaling upon CD20 cross-
linking.
One of the first chimeric antibodies to enter the
clinic, rituximab [brand names Rituxan (USA) and
MabThera (Europe)], has validated CD20 as a
prominent therapeutic target. Rituximab is now
used routinely in the treatment of NHL, either as a
single agent or (most often) in combination with
chemotherapy. Yet, in other B cell malignancies
such as chronic lymphocytic leukemia (CLL),ritux-
imab appears far less effective.
Ofatumumab (clone 2F2, IgG1κ) was generated
amongst a panel of fully human CD20 mAbs [33].
Characterization of this panel and comparison to
rituximab identified ofatumumab as an extremely
potent inducer of CDC, in addition to it being able
to effectively induce ADCC (Fig.2) [33,34].The dis-
Figure 4. CD20 expression in B cell on-
togeny. B cell development is a multi-
staged process that begins with a
pluripotent hematopoietic stem cell
and ends with the formation of an anti-
body-producing plasma cell. CD20 ex-
pression is restricted to the pre-B cell 
to memory B cell stage. B cell malig-
nancies, as indicated, can occur at al-
most any stage of B cell development,
producing a variety of distinct
leukemias and lymphomas.
Figure 5. Epitope of ofatumumab. Peptide scanning and mutation studies
revealed the binding epitope of ofatumumab on CD20. Amino acids con-
tributing to ofatumumab binding are indicated in red [35]. Amino acids
essential for rituximab, but not ofatumumab binding are indicated in
yellow [36, 37].© 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 1165
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ing a mutagenesis approach revealed that, where-
as the epitope for rituximab lies entirely within the
larger of the two extracellular loops [36, 37], ofatu-
mumab binds to a motif that includes the small ex-
tracellular loop (Fig. 5) [35]. With this small loop
being located close to the cell membrane, it is hy-
pothesized that ofatumumab binding allows a very
efficient localization of complement on the cell sur-
face. Indeed, increased C1q binding, leading to
more C4c and C3b fixation, and enhanced CDC ac-
tivity have been observed with ofatumumab com-
pared to rituximab [33, 34, 38]. For instance, Bmax
for binding of C4c to ofatumumab-coated Daudi
cells is 3507 (mean fluorescence intensity, meas-
ured in FACS analysis) versus 2410 for rituximab,
with corresponding EC50 values of 0.05 μg/mL ver-
sus 0.42 μg/mL [33].
Ofatumumab not only induced CDC at low anti-
body concentrations, it was also able to lyse cells
with low levels of CD20 expression and those with
high expression of CDC-defense molecules CD55
and CD59. Using a panel of CD20-transduced hu-
man CEM T cell clones expressing varying num-
bersof CD20 molecules, ofatumumab was found to
lyse cells with as few as 4000 CD20 molecules at
their cell surface (Fig. 6A). CD20-low-expressing,
rituximab-resistant CLL cells were also efficiently
lysed by ofatumumab (Fig. 6B) [33]. Pharmacoki-
netic analyses in SCID mice (in which no antibody
response against the injected antibody can be
mounted) indicated expected serum half-life times
in vivo: 19 ± 0.4 days for ofatumumab, 15 ± 0.8 days
for rituximab2.
The pharmacological results for ofatumumab
indicated its clinical potential: being an effective
killer of (malignant) B cells, ofatumumab could be
efficacious as monotherapy, in addition to having
an expected enhanced efficacy in combination with
other agents. Patients with an existing or acquired
resistance to other (CD20 directed) therapies might
benefit from a more potent ofatumumab-based
therapy. Interestingly, acquired resistance to ritux-
imab was recently found to be associated with
down-regulation of CD20 expression and up-regu-
lated expression levels of complement-regulatory
Figure 6. Potent B cell killing capacity of ofatumumab. (A) Anti-CD20-me-
diated CDC of CEM cells expressing varying amounts of CD20. The range
of CD20 expression in follicular lymphoma and B cell chronic lymphatic
leukemia is indicated, showing the potential for ofatumumab of killing
cells that are resistant to rituximab. (B) Primary CLL cells are efficiently
killed by ofatumumab with human effectors. Human blood (whole blood)
was fractionated into polymorphonuclear (PMN) or mononuclear cells
(MNC), or into complement containing plasma. Specific target cell lysis
was assessed in 51Cr release assays (*, significant difference compared to
“no antibody”, p < 0.001). (C) Leukemic B cell counts in B-CLL patients re-
ceiving four weekly infusions (1× 500 mg and 3× 1000 mg) of ofatumum-
ab. Adapted from [13, 33, 35].
tinction of ofatumumab with regard to CDC induc-
tion was found to be linked to binding to a unique
epitope on CD20 [35].Epitope mapping studies us-
2 In addition to rituximab, two other CD20-antibodies have been FDA-ap-
proved for human use: Bexxar (tositumomab and 131I-labeled tositu-
momab) and Zevalin (90Y- or 111In-labeled ibritumomab tiuxetan). These
antibodies are used in a different therapeutic setting, namely as radioim-
munotherapeutic, which benefits from the relatively short half-life of
mouse antibodies in humans. Whereas Zevalin is based on the same
mouse antibody parent as rituximab (i.e., C2B6), Bexxar is based on B1, an
antibody with an intrinsic activity that is entirely different from ofatumum-
ab and rituximab/C2B6 (reviewed in [29]). It is relatively inactive in com-
plement activation, but in contrast promotes programmed cell death.Biotechnology
Journal
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protein CD55 [39]. In addition, B cell malignancies
characterized by low CD20 expression levels, such
as CLL, or those with high expression levels of
complement-regulatory proteins may now be eligi-
ble for CD20 directed therapy with ofatumumab.
Results from Phase I/II studies in B-CLL and
follicular lymphoma supported the therapeutic po-
tential of ofatumumab. Ofatumumab safety and ef-
ficacy was tested in a multicenter, dose-escalating
study of 33 patients with relapsed or refractory CLL
[13]. The results of this study are summarized in
Table 2. Following four weekly ofatumumab doses,
a rapid, substantial and consistent B cell depletion
was observed (Fig. 6C), and a 50% overall response
rate reached. Importantly, ofatumumab was well
tolerated,and the maximum tolerated dose was not
reached. The primary safety observation was oc-
currence of infusion reactions in patients receiving
the highest dose; however, their occurrence de-
creased with subsequent dosing and the incidence
was comparable to that described for rituximab.
Hence, the potent CDC induction by ofatumumab
did not appear to trigger increased systemic ad-
verse reactions.Again, the close binding proximity
of ofatumumab to the cell membrane likely results
in highly efficient complement deposition on B cell
membranes,without high levels of systemic release
of activated complement components.
In follicular NHL, a Phase I/II dose-escalation
trial included 40 patients receiving four weekly
ofatumumab infusions (Table 2).Again,a rapid and
sustained B cell depletion was observed at all dos-
es, with B cell recovery corresponding to dose lev-
els, and an overall response rate up to 63% was
reached. Notably, in a subgroup of patients who
previously received rituximab therapy but had re-
lapsed, the overall response rate was 64%. In con-
trast,re-treatment with rituximab has been report-
ed to result in an overall response rate of 35–40%
[40, 41].
In both CLL and follicular NHL, ofatumumab is
now being evaluated in pivotal Phase III studies.In
addition, a Phase II study in relapsed diffuse large
B cell lymphoma patients has been initiated.For all
these B cell malignancies, it is understood that
there is clear potential for CD20-directed therapy
(either as monotherapy or in combination with oth-
er treatment modalities).With ofatumumab having
such a strong CDC activity, in addition to potent
ADCC, even on cells with high expression of com-
plement regulatory proteins or low expression of
CD20, it can be expected that this new human an-
tibody will be able to make a difference for patients
resistant or refractory to current therapeutics.
5 Zalutumumab: Disconnecting EGFR 
molecules, connecting effector cells 
The central role of the EGFR/ErbB family mem-
bers in cell migration, proliferation, survival, and
transformation identified these transmembrane
receptors as targets for cancer therapeutic ap-
proaches. This family includes ErbB1/HER1/
EGFR,ErbB2/HER2/Neu,ErbB3/HER3 and ErbB4/
HER4 [42].The first ErbB receptor-targeting anti-
body approved by the United States FDA in 1998
was trastuzumab (brand name Herceptin), for the
treatment of HER2-positive breast cancer. For tar-
geting of EGFR/HER1,cetuximab (brand name Er-
bitux) and panitumumab (brand name Vectibix)
are currently approved for clinical use.
Zalutumumab (clone 2F8) targets EGFR,a 170-kDa
transmembrane glycoprotein containing a tyrosine
kinase domain and regulatory domain in the C
terminus [43]. EGFR is expressed on normal cells
at levels ranging from 20 000 to 200 000 receptors
per cell.The intracellular kinase domain is activat-
ed upon ligand binding to the EGFR extracellular
domain. EGFR plays a role during embryogenesis
in the morphogenesis of organs like teeth, brain,
reproductive and gastrointestinal tracts, and car-
diovascular system. Physiologically, EGFR has an
essential role in wound healing and normal epithe-
lial regeneration of organs. EGFR activation has
been described to trigger processes such as prolif-
eration,apoptosis,migration,angiogenesis and dif-
ferentiation [44–47].
Rowinsky et al. [48] showed that EGFR plays a
role in the transformation and progression of car-
cinomas. EGFR overexpression in tumor cells can
produce up to 2 million EGFR molecules per cell,
and has been correlated to a more malignant tumor
grade as well as a reduced patient survival [48, 49].
Additionally, mutant forms of EGFR and overex-
pression of EGFR ligands have been recognized to
promote cancer progression in a range of solid tu-
mors.
Next to mAbs,another class of drugs is success-
fully employed to target EGFR for cancer therapy:
small molecule tyrosine kinase inhibitors (TKI),
targeting the ATP-binding pocket of the EGFR ki-
nase domain.TKI, including the U.S. FDA and Eu-
ropean Medicine Agency (EMEA) approved agents
gefitinib (Iressa), erlotinib (Tarceva) and lapatinib
(Tykerb),are oral,low-molecular-weight inhibitors
of the EGFR tyrosine kinase located in the intra-
cellular part of the receptor. TKI block EGFR ki-
nase activity and EGFR downstream signaling [50].
In contrast to the approach using mAb,tyrosine ki-
nase inhibition is not strictly EGFR-specific and
some cross-reactivity with other ErbB family mem-© 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 1167
bers,e.g.,HER2,may occur [51].mAbs and TKI also
differ in pharmacological and pharmacokinetic
properties. EGFR antibodies, being large proteins
(~150 kDa), are normally administered intra-
venously, in contrast to TKI, which are small syn-
thetic molecules (~500 Da) and are taken orally.Ac-
cording to the FDA labels, antibody half-lives in
blood (for cetuximab 3.1–7.8 days; for panitumum-
ab 3.6–11.9 days, allowing for dosing every 7, or
14 days, respectively) are longer than those of
small-molecule agents (gefitinib, ~48 h; erlotinib,
~36 h; allowing for once-daily dosing). Further,
pharmacokinetic studies demonstrated that plas-
ma concentrations of TKI vary substantially be-
tween patients [52].
An important functional difference between
TKI and EGFR antibodies lies in the antibodies’
ability to attack cancer cells through a combination
of mechanisms.TKI,being small,are indeed able to
pass through cell membranes and can act on tar-
gets in the cytoplasm regardless of their cellular lo-
cation, yet once in the cell they do only one thing:
inhibit kinase activity. For several types of cancer,
certain (secondary) mutations in the EGFR kinase
domain have been reported that confer resistance
to TKI [53–55]. For antibodies, being able to recruit
immune effector functions in addition to having di-
rect effects on EGFR activity, resistance to therapy
is unlikely to arise through mutations in the EGFR
kinase domain. Indeed (as described below), clini-
cally relevant EGFR mutations did not influence
the activity of EGFR antibodies.
Zalutumumab, a high-affinity human IgG1K
EGFR antibody, potently inhibits tumor growth in
xenograft models by engaging two mechanisms 
of action (Fig. 2) [56]. Firstly, EGFR signaling is
blocked. This was observed as a reduction in re-
ceptor phosphorylation and is most effective at sat-
urating antibody concentrations. Secondly, anti-tu-
mor effects are mediated by Fc-mediated ADCC.
This mechanism is already active at low target oc-
cupancy. Together, these properties make zalutu-
mumab highly effective in cancer disease models,
being able to eradicate tumors even at low and in-
frequent doses.
As inhibition of EGFR signaling was recognized
as an important mechanism not only of zalutu-
mumab, but also of other EGFR antibodies like ce-
tuximab, we investigated the influence of (lung
cancer-derived) mutations that change the EGFR
kinase activity,on tumor cell killing [57].An EGFR-
responsive cell line model was established, in
which cells expressed tumor-derived EGFR muta-
tions (L858R, G719S, delE746-A750 and secondary
mutation T790M). In these, two prototypic TKI,
gefitinib and erlotinib, demonstrated the expected
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reduced or abolished activities. In sharp contrast,
anti-tumor effects of zalutumumab and cetuximab
were not impacted by these mutations.Not only did
inhibition of EGFR signaling and cell growth by the
EGFR antibodies remain intact, their ADCC activi-
ty was also unaffected.
Remarkably, it was found that, while zalutu-
mumab efficiently inhibited EGFR signaling, the
intact antibody was more efficient in this than Fab
fragments [58]. Hence, bivalent binding to EGFR
contributed to zalutumumab’s mechanism of ac-
tion.To understand the molecular mechanisms un-
derlying this, we used protein tomography to visu-
alize EGFR conformations on EGFR-overexpress-
ing cells in its monomeric (resting),its EGF-stimu-
lated conformation and its zalutumumab-inhibited
conformation [58] (Fig. 7). This technique allowed
us to observe individual cell membrane-localized
EGFR molecules at a level of detail not previously
obtainable, i.e., where separate protein domains
could be discerned. Monomeric, resting EGFR
ectodomains were found to be highly flexible mol-
ecules, showing that EGFR is able to switch be-
tween a tethered (auto-inhibited) conformation
Figure 7. Conformation of zalutumumab-bound EGFR. Shown are tomo-
grams of zalutumumab-bound EGFR. In the lower panels, the tethered
crystal structure of sEGFR (PDB: 1nql, shown as a ribbon representation)
was superimposed into EGFR ectodomain tomograms. The crystal struc-
ture of human immunoglobulin 1 {PDB: (A) 1HZH [57], (B) 1IGY [58]}
was superimposed into zalutumumab (green). Panels A and B show a to-
mogram of a zalutumumab molecule monovalently bound to EGFR. The
complex was marked by anti-EGFR-3.5-nm colloidal gold-conjugated pro-
tein A intracellular labeling only. Dotted line in (B) marks the zalutumum-
ab docking site on EGFR. The EGFR ectodomain structure is condensed
and resembles the tethered EGFR conformation, when zalutumumab is
bound (n=4). (C, D) Tomograms in which one zalutumumab antibody
molecule binds two EGFR molecules. Zalutumumab binds one EGFR mol-
ecule with each of its Fab arms, spatially separating the two receptors
(n=2). The extra volume present on EGFR domain I (white) likely repre-
sents carbohydrate chains. From [58].Biotechnology
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and extended (pre-activated) “pistol-shaped” con-
formation (as described before, [59, 60]). In con-
trast, zalutumumab-bound EGFR conformations
were condensed and appeared to be locked in one
specific,very compact (and inactive) conformation.
Bivalent binding and EGFR cross-linking by zalu-
tumumab was found to spatially separate the EGFR
molecules’ intracellular kinase domains to an ex-
tent,which appeared incompatible with kinase do-
main interaction and induction of signaling.
For other EGFR antibodies (in particular for ce-
tuximab), antibody-induced down-modulation of
EGFR has been postulated as part of the mecha-
nism of action [61, 62]. Zalutumumab was found to
induce moderate EGFR down-modulation [63].
Having potent anti-tumor activity in laboratory
settings, even at doses where other EGFR antibod-
ies were found to be much less effective, zalutu-
mumab was recognized as having the properties
required for treatment of a variety of cancers, and
was awarded fast track status from the U.S.FDA for
head and neck cancer patients who have failed
standard therapies (Table 3).Its efficacy is also ex-
plored for the treatment of non-small cell lung can-
cer, in combination with chemo-radiation therapy,
and colorectal cancer in combination with irinote-
can chemotherapy. Phase I/II results in squamous
cell carcinoma of the head and neck (SCCHN)
showed good responses, as demonstrated by two
types of scanning (Table 2) [64].Assessed by FDG-
PET, which visualizes tumor metabolism, 7 of 18
evaluable patients achieved partial metabolic re-
sponse (PMR) (Fig. 8) and 4 had stable metabolic
disease (SMD) 1 week after their fifth and last in-
fusion. In the two highest dose groups, 9 out of 11
patients obtained PMR or SMD.These results were
confirmed by computerized tomography (CT scan).
At present, the field of EGFR-targeted thera-
peutics is evolving rapidly as better insights in
EGFR biology and clinical trial data become avail-
able. Although objective clinical responses have
been frequently observed during EGFR-targeted
therapies, many patients develop therapy resist-
ance. Here, it becomes clear that a better under-
standing of the mechanism of action of EGFR ther-
apeutics, and studies on how tumor cell resistance
can be circumvented will further contribute to op-
timize treatment regimes. Indeed, zalutumumab,
displaying novel modes of action that distinguish it
from other EGFR antibodies, has potential as ef-
fective treatment in a variety of cancers.
6 Umabs: The new standard
Antibody therapeutics make a profound impact on
the treatment of cancer. The technologies used to
generate new therapeutic antibodies have become
highly refined. The first -omabs brought promise
but also disappointments, and it was the -ximabs
and -zumabs that set the stage for antibody thera-
py. Now, -umabs are becoming the standard.
These fully human antibodies can be generated
using various techniques, including phage display
and transgenic technologies.The characteristics of
antibodies generated from these platforms are in-
trinsically determined by the human V repertoire
contained in the libraries/transgenic mice, and the
extent of (in vitro or in vivo) affinity maturation that
occurs. Overall, these determine the pool of anti-
bodies from which potential development candi-
dates can be selected.The quality of the final clin-
ical candidate, however, is strongly dependent on
the entire lead candidate selection process.We be-
lieve that our approach of antibody library genera-
tion followed by rational and science-based library
screening, significantly contributes to selecting an
optimal final product.
Several other methods of improving the re-
sponse rates of mAbs in cancer therapy have been
investigated and are now in early clinical evalua-
tion. For instance, combinations of antibodies are
being explored as an approach to overcome the of-
ten-observed tumor escape from antibody therapy.
An example here is the combination of HER2 mAbs
recognizing different epitopes on the HER2 extra-
cellular domain,which were found to give superior
anti-tumor activity compared to the individual an-
tibodies,both in vitro and in vivo [65].Also,the fea-
sibility of combining various antibodies with ritux-
imab,e.g.,Campath,has been investigated [66].Re-
cently, we have reported a remarkable synergy for
EGFR antibodies [67]. Individually, these antibod-
ies have potent activity in ADCC (as described
above), whereas complement-mediated lysis is not
Figure 8. Clinical effect of zalutumumab. PET scan from a patient with 
SCCHN showing a partial metabolic response upon treatment with zalu-
tumumab (8 mg/kg).© 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 1169
apparent. Combining IgG1 EGFR-antibodies rec-
ognizing different,non-overlapping epitopes,how-
ever, resulted in potent complement activation and
effective lysis of tumor cells. These findings indi-
cate unexpected qualities of EGFR antibody com-
binations that can be deployed for novel cancer
treatments.
It is recognized that certain therapeutic applica-
tions may benefit from optimizations of the anti-
body format,and this is sprouting an extensive line
of research focusing on engineering for enhanced
effector function,controlling of half-life,increasing
stability and improving tumor and tissue penetra-
tion (extensively reviewed in [68]). For instance,
the affinity of the Fc domain to Fc receptors can be
modified by changing the sugar structures on anti-
bodies (glyco-engineering) [69]. With this, effica-
cies can be increased, dosing lowered and poten-
tially side effects minimized.
The continuing increase in knowledge of anti-
body biology and mechanisms of action, and the
application of this knowledge in understanding the
antibodies interactions at molecular, cellular and
organism levels, will enable us to further improve
and expand the therapeutic application of antibod-
ies in human diseases. Zanolimumab, ofatumumab
and zalutumumab illustrate how each therapeutic
antibody harbors unique features,which can be ex-
ploited to optimally target specific cancer indica-
tions, and provide new treatment options for pa-
tients.
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